Neuroscience
From Fierce Biotech:
Key AZ/Targacept depression drug flunks first Phase III test
By John Carroll
November 8, 2011 — 6:49am ET
[snippet]
"The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's struggling R&D operation another stinging setback and walloping Targacept with a meltdown in its share value this morning."
[snippet]
Read the full article
- Alzheimer's Disease: Aaic Review From "fierce Biotech"
Alzheimer's roundup: Investigators carve out small gains against a brutal disease Fierce Biotech By John Carroll July 18, 2013 Read the article...
- Alzheimer's Disease: Negative Bapineuzumab Findings In Phase Iii Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release. From FierceBiotech: UPDATED: Pfizer, J&J...
- Clinical Trials: Evp-6124 Phase 2b Clinical Trial In Schizophrenia
From Drug Discovery & Development: Positive Study Results for Schizophrenia Drug Drug Discovery & Development December 05, 2011 "EnVivo Pharmaceuticals announced the analysis of a completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable...
- Sage Therapeutics
A report from Fierce BioTech: Third Rock Ventures Launches SAGE Therapeutics to Address CNS Disorders with Critical Unmet Needs Posted October 18, 2011 [snippet] "Third Rock Ventures, LLC today announced the formation of SAGE Therapeutics. The company...
- Business World: Novartis, Multiple Sclerosis, Fty720, & Betaseron
From The Wall Street Journal's Health Blog: AUGUST 17, 2009, 11:12 AM ET Novartis’s Big Plans for Multiple Sclerosis By Jeanne Whalen [snippet] The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis...
Neuroscience
TC-5214 Depression Phase III Results
From Fierce Biotech:
Key AZ/Targacept depression drug flunks first Phase III test
By John Carroll
November 8, 2011 — 6:49am ET
[snippet]
"The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's struggling R&D operation another stinging setback and walloping Targacept with a meltdown in its share value this morning."
[snippet]
Read the full article
- Alzheimer's Disease: Aaic Review From "fierce Biotech"
Alzheimer's roundup: Investigators carve out small gains against a brutal disease Fierce Biotech By John Carroll July 18, 2013 Read the article...
- Alzheimer's Disease: Negative Bapineuzumab Findings In Phase Iii Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release. From FierceBiotech: UPDATED: Pfizer, J&J...
- Clinical Trials: Evp-6124 Phase 2b Clinical Trial In Schizophrenia
From Drug Discovery & Development: Positive Study Results for Schizophrenia Drug Drug Discovery & Development December 05, 2011 "EnVivo Pharmaceuticals announced the analysis of a completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable...
- Sage Therapeutics
A report from Fierce BioTech: Third Rock Ventures Launches SAGE Therapeutics to Address CNS Disorders with Critical Unmet Needs Posted October 18, 2011 [snippet] "Third Rock Ventures, LLC today announced the formation of SAGE Therapeutics. The company...
- Business World: Novartis, Multiple Sclerosis, Fty720, & Betaseron
From The Wall Street Journal's Health Blog: AUGUST 17, 2009, 11:12 AM ET Novartis’s Big Plans for Multiple Sclerosis By Jeanne Whalen [snippet] The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis...